Fasting serum insulin and lipid levels in men with epilepsy

Neurology

Volumn 60, Issue 4, 2003, Pages 571-574

  Pylvänen, Virpi ^a,c   Knip, M ^b   Pakarinen, A J ^a   Turkka, J ^a   Kotila, M ^b   Rattya J ^a   Myllyla V V ^a   Isojarvi J I T ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Department of Neurology ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; INSULIN; OXCARBAZEPINE; VALPROIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; EPILEPSY; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0242684478     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000048209.07526.86     Document Type: Article

References (36)

1. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-372.
2. Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet C, et al., eds. Epileptic syndromes in infancy, childhood and adolescence. London: Libbey, 1992:313-327.
3. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine in the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:756-771.
4. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998;97:387-397.
5. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-108.
6. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;4:1383-1388.
7. Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
8. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
9. Isojärvi JIT, Taubøll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risks in valproate treated women. Am J Med 2001;111:290-296.
10. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
11. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119-126.
12. Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol 1993;39:623-632.
13. Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocr 1994;12:38-44.
14. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged med with dyslipidemia. N Engl J Med 1987;317:1237-1245.
15. Rättyä J, Turkka J, Pakarinen AJ, et al. Reproductive endocrine effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001;56:31-36.
16. Haffner SM, Karhapää P, Nykkänen L, Laakso M. Insulin resistance, body fat distribution and sex hormones in men. Diabetes 1994;43:212-219.
17. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis. A study in castrated, cholesterol-fed rabbits. Circ Res 1999;84:813-819.
18. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;69:65-69.
19. Isojärvi JIT, Pakarinen AJ, Myllylä VV. Serum lipids during carbamazepine medication - a prospective study. Arch Neurol 1993;50:590-594.
20. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllylä VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35:1217-1220.
21. Proposal for revised classification of epilepsies and epileptic syndromes: from the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389-399.
22. Shorvon SD. Antiepileptic drugs. In: Handbook of epilepsy treatment. Oxford: Blackwell Science, 2000:85-162.
23. Andersen L, Dinesen B, Jørgensen PN, et al. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-582.
24. 2+/dextran sulphate in its enzymatic measurement. Clin Chem 1978;24:931-933.
25. Keränen T, Jolkkonen J, Klosterskov-Jensen P. Single-dose kinetics of oxcarbazepine after treatment simetidine or erythromycine. Epilepsia 1990;31:641.
26. Stephen LJ, Kwan P, Shapir D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1004.
27. Vorum H, Gram L, Honoré B. Valproate and palmitate binding to serum albumin in valproate treated patients. Relation to obesity. Epilepsy Res 1993;16:55-64.
28. Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993;46:199-204.
29. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670.
30. Gidal BE, Anderson GD, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. Epilepsy 1996;9:234-241.
31. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
32. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990;70:699-704.
33. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525-531.
34. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diaoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027-1032.
35. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome J Clin Endocrinol Metab 1996;81:3299.
36. Larkin JG, McKee PJW, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:65-71.